Cargando…
Pharmacokinetic and Safety Profiles of a Fixed‐Dose Combination of Amlodipine, Valsartan, and Atorvastatin: A 3‐Period Replicate Crossover Study
The objective of study was to compare the pharmacokinetic and safety profiles of a fixed‐dose combination (FDC) formulation of 5/160/20 mg amlodipine/valsartan/atorvastatin with those of separate formulations of a 5/160‐mg amlodipine/valsartan tablet and a 20‐mg atorvastatin tablet. This was a rando...
Autores principales: | Kim, Seokuee, Ko, Jae‐Wook, Kim, Jung‐Ryul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187173/ https://www.ncbi.nlm.nih.gov/pubmed/31373174 http://dx.doi.org/10.1002/cpdd.727 |
Ejemplares similares
-
No pharmacokinetic interactions between candesartan and amlodipine following multiple oral administrations in healthy subjects
por: Kim, Jung-Ryul, et al.
Publicado: (2018) -
Amlodipine and valsartan as components of a rational and effective fixed-dose combination
por: Waeber, Bernard, et al.
Publicado: (2009) -
Co-Administration of Vonoprazan, Not Tegoprazan, Affects the Pharmacokinetics of Atorvastatin in Healthy Male Subjects
por: Hwang, Sejung, et al.
Publicado: (2021) -
Pharmacokinetics of fixed-dose combination of atorvastatin and metformin compared with individual tablets
por: Ghim, Jong-Lyul, et al.
Publicado: (2019) -
Comparisons of the pharmacokinetics and tolerability of fixed-dose combinations of amlodipine besylate/losartan and amlodipine camsylate/losartan in healthy subjects: a randomized, open-label, single-dose, two-period, two-sequence crossover study
por: Choi, YoonJung, et al.
Publicado: (2016)